The Transition Beyond the Acute Phase of COVID-19 Pandemic in Africa
WHO Lifts the Status of coronavirus disease (COVID-19) Pandemic as a Public Health Emergency of International Concern (PHEIC) On May 5, 2023, more than three (3) years since the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern (PHEIC), the status was lifted. The Emergency Committee on the coronavirus disease (COVID-19) […]
Statement from Africa CDC on the Pandemic Fund[1]
Addis Ababa, Ethiopia, 15 February 2023 – Africa CDC welcomes the call by the Pandemic Fund on 3rd February 2023, seeking Expressions of Interest (EOI) for potential projects to be funded under its first Call for Proposals. Africa CDC further encourages African Union (AU) Member States to actively participate in the Pandemic Fund activities and […]
Statement on the 1st Africa CDC Youth Pre-Conference
UNDER THE THEME “MEANINGFUL YOUTH ENGAGEMENT FOR ADVANCING SUSTAINABLE HEALTH SECURITY IN AFRICA” 10-11 DECEMBER 2022 A side event at the margins of the 2nd International Conference on Public Health in Africa (CPHIA 2022) BACKGROUND Africa continues to experience the highest incidence of public health emergencies annually. Therefore, the African Union Heads of State, Governments, […]
Joint Statement on Dose Donations of COVID-19 Vaccines to African Countries
29 November 2021| Addis Ababa| Geneva. Building on lessons learned from our collective experience with dose donations over the past several months, the African Vaccine Acquisition Trust (AVAT), the Africa Centres for Disease Control and Prevention (Africa CDC) and COVAX wish to draw the attention of the international community to the situation of donations of […]
Africa Centres for Disease Control and Prevention’s Statement regarding the new SARS-COV-2 virus variant B.1.1.529
On 25 November 2021, the Network for Genomics Surveillance in South Africa (NGS-SA) announced the detection of a new variant of the SARS-COV-2, the virus that causes COVID-19, following genomic sequencing. This variant is currently labelled as lineage B.1.1.529. The emergence of this new variant coincides with a sudden increase in cases in the Gauteng […]
Statement on UK travel restrictions, September 24, 2021
The Africa Centres for Disease Control and Prevention (Africa CDC), a Specialised Technical Institution of the African Union, noted with deep concern the planned changes to international travel rules in the context of the COVID-19 pandemic, communicated by the Government of the United Kingdom (U.K), which will be enforced starting at 4:00 am on Monday […]
Kenya’s Statement on the Africa CDC Trusted Travels Platform
Your Excellencies, distinguished dignitaries, members of the media, ladies and gentleman, it gives me great pleasure to be joining my colleague Ministers and our very good friends at the Africa CDC to review the Joint Continental Strategy on COVID-19 since it was launched in February 2021. I am also proud to reaffirm and re-commit the […]
UPDATE: Statement to Member States regarding thromboembolic events after vaccination with Janssen COVID-19 vaccine (Johnson & Johnson)
Context The COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), is a human adenovirus based vaccine which is administered as a single dose regimen to prevent COVID-19. The Janssen COVID-19 vaccine has been issued an Emergency Use Authorization by the United States (U.S). Food and Drug Administration (FDA). It is authorized in the European […]
Statement on donation and distribution of Oxford-AstraZeneca COVID-19 vaccine through AVATT
21 APRIL 2021 The Africa Centres for Disease Control and Prevention (Africa CDC), seeks to clarify the management of the Oxford-AstraZeneca COVID-19 vaccines received through a donation to the African Union’s African Vaccine Acquisition Task Team (AVATT), the entity responsible for leading the continent’s COVID-19 vaccine strategy. In mid-March, AVATT shipped 925,000 of doses Oxford-AstraZeneca COVID-19 vaccines […]
Statement to Member States regarding thromboembolic events after vaccination with Janssen COVID-19 vaccine (Johnson & Johnson)
Context The COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), is a human adenovirus based vaccine which is administered as a single dose regimen to prevent COVID-19, with a demonstrated efficacy of 66% overall and 57% in a context with predominance of the 501Y.V2 SARS-COV-2 variant. On 27th February 2021 the U.S. Food and […]